AbstractPDF
Abstract
Severe acute respiratory syndrome (SARS) has recently been recognised as a newly emerging infectious disease with significant morbidity and mortality. It has been suggested that (early) antiviral treatment with ribavirin and high-dose glucocorticosteroids may be beneficial. We have summarised the available data on ribavirin to facilitate decision-making when confronted with (suspected) SARS.
